Feitosa F E L, Sampaio Z S, Alencar C A, Amorim M M R, Passini R
Maternidade-Escola, Universidade Federal do Ceará, Fortaleza, State of Ceará, Brazil.
Int J Gynaecol Obstet. 2006 Aug;94(2):91-5. doi: 10.1016/j.ijgo.2006.04.031. Epub 2006 Jul 7.
To compare sublingual with vaginal misoprostol for the induction of labor.
This double-blind clinical trial randomized 150 women to receive every 6 h 25 mug of sublingual misoprostol and vaginal placebo or 25 mug of vaginal misoprostol and sublingual placebo. Maternal and neonatal outcomes were analyzed and risk ratios (RRs) with 95% confidence intervals (CIs) calculated. The significance level was 5%.
Vaginal delivery rates were 57% in the sublingual group and 69% in the vaginal group (RR, 0.8; 95% CI, 0.6-1.1). There were 11 cases of fetal distress in the sublingual group and 4 cases in the vaginal group (RR, 2.7; 95% CI, 0.9-8.2). There were no significant differences in the number of doses needed, interval between first dose and delivery, incidence of contractility disturbances, or neonatal results.
The administration of misoprostol 25 mug by the sublingual route was neither more effective nor safer than the same dose administered vaginally.
比较舌下含服米索前列醇与阴道用米索前列醇引产的效果。
这项双盲临床试验将150名妇女随机分为两组,一组每6小时舌下含服25微克米索前列醇并给予阴道安慰剂,另一组每6小时阴道给予25微克米索前列醇并给予舌下安慰剂。分析产妇和新生儿结局,并计算风险比(RR)及95%置信区间(CI)。显著性水平为5%。
舌下含服组阴道分娩率为57%,阴道用药组为69%(RR,0.8;95%CI,0.6 - 1.1)。舌下含服组有11例胎儿窘迫,阴道用药组有4例(RR,2.7;95%CI,0.9 - 8.2)。在所需剂量数、首剂与分娩间隔、宫缩紊乱发生率或新生儿结局方面无显著差异。
舌下含服25微克米索前列醇在引产效果上并不比阴道给予相同剂量更有效或更安全。